We celebrate our scientists at the Clinical HIV Research Unit (CHRU) & thank all our clinical trial participants
They test new medicines to find better &easier ways to treat diseases like HIV, TB and HIV-associated cancers which advance science & benefit society.
They worked tirelessly to test the Johnson & Johnson COVID-19 vaccine to find a safe vaccine for South Africans and people across the world.
CHRU’s national & international standing
- Ground-breaking research impacting on SA’s treatment guidelines
- 33 clinical trials over the last five years
- At the forefront of international and SA public health research.
- Our scientists participated in Janssen’s ENSEMBLE study as well as the Sisonke study for healthcare workers in 2020 and early 2021. In April this year, the World Health Organisation’s (WHO)Strategic Advisory Group of Experts (SAGE) on immunisation issued interim recommendations for the use of the Janssen Ad26.CoV2.S vaccine against COVID-19.
- We were involved in the Study Strategic Timing of Antiretroviral Treatment (START) study which showed that HIV-infected people have a lower risk of developing AIDS with the early introduction of antiretroviral treatment or ART. This study laid the foundations for WHO’s and the South African National Department of Health’s (NDOH) Test and Treat approach to HIV.
- We were involved in the HPTN 052 study which determined that early introduction of ART for a partner with HIV whose partner does not have HIV helps prevent HIV transmission. Following the interim results of the study, WHO recommended that ART be offered to all HIV-positive people whose partners are HIV-negative.
- The STREAM study evaluated a new regimen and slashed treatment duration for multi-drug resistant (MDR) TB.
- We participated in the NIH’s ACTG A5279 study which looked at TB prevention in HIV positive people. The study showed that a one-month, ultra-short TB preventive course could be an important tool in the global control of HIV-associated TB.
- The safety and efficacy results of the Nix-TB TB Alliance trial that CHRU was part of were presented to the United States Government’s Food and Drug Administration Advisory Committee in June 2019.
- CHRU participated in the Bedaquiline Clinical Access Program which led to the NDoH’s introduction of the drug Bedaquiline as the standard care of treatment for MDR-TB in 2018.
CHRU’s research agenda is aligned with the World Health Organisation, the National Department of Health, and the Strategic Research Plan of the University of the Witwatersrand.